On a roll, Ver­tex racks up im­pres­sive PhI­II da­ta for VX-659 com­bos in cys­tic fi­bro­sis

Ver­tex $VRTX has come up with a stack of pos­i­tive Phase III da­ta points for their cys­tic fi­bro­sis triple in­clud­ing the ex­per­i­men­tal VX-659. And its R&D group says they can ride these re­sults all the way to an FDA ap­proval.

Right now we’re just get­ting the pri­ma­ry end­point read­out, which is im­pres­sive. VX-659 is be­ing cred­it­ed with a 14% place­bo-ad­just­ed im­prove­ment from base­line in FEV1 for pa­tients with one F508del mu­ta­tion and one min­i­mal func­tion mu­ta­tion, with a clear score on the p val­ue (p<0.0001). 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER